IRVINE, Calif. & AMSTERDAM—Agendia Inc. reported recently that its MammaPrint Breast Cancer Risk-of-Recurrence Test is the only molecular diagnostic indicated for use in patients whose breast cancer has spread to their lymph nodes (node-positive), according to the Cancer Care Ontario Guidelines. The guidelines also recommend the test for patients with node-negative breast cancer. MammaPrint uses a 70-gene expression profile to stratify patients with either a low or high risk of recurrence over 10 years.

 

“We are pleased that the new guidelines now provide access to both centralized microarray and local next-generation sequencing platforms for Canadian patients and healthcare providers, and that the agency recognizes that MammaPrint is the only assay with enough evidence to be used in such a high-risk group of patients,” Dr. William Audeh, medical oncologist and chief medical officer at Agendia, commented in a press release.